By Ben Hirschler LONDON (Reuters) - Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The U.S. drugmaker said on Monday it was establishing a gene therapy platform to study potential treatments, led by a top UK expert, and had struck a deal with privately owned U.S. biotech firm Spark Therapeutics to develop a treatment for haemophilia. The Spark programme is expected to enter early-stage clinical trials for haemophilia B in the first half of 2015. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment